Cargando…

Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis

Could hydroxychloroquine and quinacrine antimalarial therapy for dermatomyositis later attributed to a paraneoplasic manifestation of an ovarian cancer enhance its subsequent response to chemotherapy? Five months after being diagnosed with dermatomyositis, while somewhat improved with hydroxychloroq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cadena, Isabella, Werth, Victoria P, Levine, Pascale, Yang, Annie, Downey, Andrea, Curtin, John, Muggia, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985755/ https://www.ncbi.nlm.nih.gov/pubmed/29910834 http://dx.doi.org/10.3332/ecancer.2018.837

Ejemplares similares

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Dermatomyositis in patients with autoimmune blistering diseases()()
por: Patsatsi, Aikaterini, et al.
Publicado: (2019)

Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers
por: Dilawari, A, et al.
Publicado: (2008)

History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications
por: Muggia, Franco, et al.
Publicado: (2021)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Dermatomyositis associated with hyponatremia and anasarca
por: Grinnell, Madison, et al.
Publicado: (2021)

Editorial: Antimalarial chemotherapy in the XXIst century
por: Gomes, Paula, et al.
Publicado: (2022)

278 Photo validation study using cutaneous dermatomyositis disease area and severity index in dermatomyositis patients
por: Grinnell, M., et al.
Publicado: (2022)

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
por: Piras, Marta, et al.
Publicado: (2021)

Dermatomyositis: Muscle Pathology According to Antibody Subtypes
por: Tanboon, Jantima, et al.
Publicado: (2022)

Environmental triggers of dermatomyositis: a narrative review
por: Bax, Christina E., et al.
Publicado: (2021)

Drug-induced dermatomyositis after lacosamide: A case report
por: Gaffney, Rebecca G., et al.
Publicado: (2018)

Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis
por: Werth, Victoria P., et al.
Publicado: (2021)

Erythromelalgia associated with dermatomyositis: A case series
por: Grinnell, Madison, et al.
Publicado: (2021)

Supraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case report
por: Sharma, Sharan Prakash, et al.
Publicado: (2013)

Editorial: Antimalarial chemotherapy in the XXIst century, volume II
por: Gomes, Paula, et al.
Publicado: (2023)

The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy()()
por: Anyanwu, C.O., et al.
Publicado: (2017)

Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
por: Cheng, Hongyan, et al.
Publicado: (2019)

A screening and prevention programme serving an ethnically diverse population of women at high risk of developing breast and/or ovarian cancer
por: Smith, J, et al.
Publicado: (2009)

Geospatial Correlation of Amyopathic Dermatomyositis With Fixed Sources of Airborne Pollution: A Retrospective Cohort Study
por: Pearson, David R., et al.
Publicado: (2019)

The genomic architecture of antimalarial drug resistance
por: Cowell, Annie N, et al.
Publicado: (2019)

Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)?
por: Silverton, Alexandra, et al.
Publicado: (2016)

Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study
por: Werth, Victoria P., et al.
Publicado: (2023)

Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
por: Valls, Maia L., et al.
Publicado: (2022)

Clinico pathological study of adult dermatomyositis: Importance of muscle histology in the diagnosis
por: Karri, Sudhir Babu, et al.
Publicado: (2015)

Dermatitis Artefacta Presenting as Dermatomyositis: A Diagnostic Conundrum
por: Raizada, Annie, et al.
Publicado: (2020)

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
por: Ring, A E, et al.
Publicado: (2004)

Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
por: Zhao, Fangyuan, et al.
Publicado: (2023)

Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned
por: Granina, Evgenia, et al.
Publicado: (2020)

Gemcitabine and Docetaxel Combination Chemotherapy Induced Dermatomyositis Associated with Hand-Foot Syndrome
por: Kawada, Mayuko, et al.
Publicado: (2021)

Chemotherapy induced juvenile dermatomyositis: a novel presentation- a case report
por: Vagha, Keta, et al.
Publicado: (2022)

Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy
por: Meraner, Verena, et al.
Publicado: (2012)

Dermatomyositis and/or polymyositis as a paraneoplastic manifestation of ovarian cancer: a systematic review
por: Psomiadou, Victoria, et al.
Publicado: (2021)

Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab
por: Menteşoğlu, Dilek, et al.
Publicado: (2022)

Dermatomyositis and HIV
por: Chand, Mamata, et al.
Publicado: (2016)

Juvenile Dermatomyositis
por: Rhim, Jung Woo
Publicado: (2022)

Death by bleomycin pulmonary toxicity in ovarian dysgerminoma with pathologic complete response to chemotherapy. A case report
por: Calzas Rodríguez, Julia, et al.
Publicado: (2016)

Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis
por: Keyes, Emily, et al.
Publicado: (2021)

Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients
por: Nabatian, Adam S, et al.
Publicado: (2012)

Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series
por: Levine, Todd
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pa3ea1l0j6rjq43n6k8dl8j70o